Medical University of Graz
Graz, 8036, Austria
NCT Number: NCT04283318
In a previous study investigating the effects of intermittent fasting, our research group found evidence for higher glucose excursions and a reduced insulin response after a 36 hour fasting period as compared to an overnight fasting period in healthy subjects.
The aim of this research project is to investigate the effect of short and midterm fasting (12 hours versus 36 hours) on glucose metabolism, glucose regulatory hormones, insulin secretion and resting energy expenditure in healthy and obese people as well as in patients with type 2 diabetes.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Graz, 8036, Austria
In this clinical study, we want to examine the effects of different fasting periods (12 hours versus 36 hours) on blood sugar levels and other metabolic parameters and hormones. For this the following investigations are carried out:
The examinations are carried out on 4 different cohorts (normal healthy persons, obese patients, patients with type 2 diabetes and patients with type 1 diabetes).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Gender: Both, male and female Minimum Age: 18 years
Inclusion criteria
Cohort I (Healthy, non-obese subjects) Age >18 years; body mass index in the range of 20.0-27.0 kg/m2; fasting plasma glucose <110mg/dL
Inclusion criteria
cohort II (Obese subjects) Age >18 years; body mass index >30 kg/m2; fasting plasma glucose <110mg/dL
Inclusion criteria
Cohort III (Cohort with subjects with Type 2 Diabetes Mellitus) Age >18 years; established Diabetes mellitus type 2 on either diet or a monotherapy or combination of metformin, Dipeptidylpeptidase (DPP)-4-inhibitors or sulfonylurea
Inclusion criteria
Cohort IV (Cohort with subjects with Type 1 Diabetes Mellitus) Age >18 years; diagnosed with Type 1 Diabetes Mellitus >12 months; treated with multiple daily Insulin injectioins (MDII) or continuous subcutaneous Insulin Infusion (CSII); stable Insulin therapy as clinically assessed by the study physician; C-Peptide negative defined as 0.3 nmol/L; HbA1c <9.5%; no diabetic ketoacidosis within the last 12 months; no severe hypoglycaemia requiring external assistance within the last 12 months; running on the FreeStyle Libre 1 (Abbott, USA) intermittently-viewed continuous Glucose Monitoring System (iCGM) as Standard of care for Glucose monitoring
Exclusion criteria
(for all participants) History of cardiovascular disease; acute or chronic inflammatory disorder; heavy drinking (more than 15 drinks/week); dietary restrictions (e.g. vegetarianism and vegan); insulin Treatment (excluded subjects with Type 1 Diabetes Mellitus); corticosteroid therapy; known malignancy; women who are pregnant, breast-feeding or trying to become pregnant; history of any chronic disease process that could interfere with interpretation of study results; therapy with antidepressants within past 6 months
12h fasting (overnight)
36h fasting ( one day and two nights fasting)
Time frame: after 12 and 36 hours of fasting
Difference in the change of 2h glucose levels in an oral glucose tolerance test
Time frame: after 12 and 36 hours of fasting
differences in QUICKI
Time frame: after 12 and 36 hours of fasting
differences in Matsuda Index
Time frame: after 12 and 36 hours of fasting
differences in ISI
Time frame: after 12 and 36 hours of fasting
differences in HOMA-Index
Time frame: after 12 and 36 hours of fasting
differences in area under the curve (AUC) of glycaemic pattern in Oral glucose tolerance test
Time frame: after 12 and 36 hours of fasting
differences in bioimpedance analysis
Medical University of Graz
Other
The Effects of Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes
Acronym: PROLOG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04787952
Adiposity, Behavior
View Trial DetailsNCT01724814
Autoimmune Diseases, Diabetes Mellitus
Chula Vista, California, United States
View Trial DetailsNCT06945419
Body Weight, Body Weight Changes
Daytona Beach, Florida, United States
View Trial DetailsNCT06592261
Body Weight, Diabetes Mellitus
New York, United States
View Trial Details